ESLOY 0MSFT 7.08META -0.85HLPR.TO -0.02VDY.TO 0.38VGG.TO -0.01BIP.UN.TO 0.8TOU.TO -0.5
Abbott Labs (ABT)

NYSE:ABT

Abbott Labs (ABT)

90.75
+2.92 (3.32%)
as of Jun 23, 2026, 5:46:44 pm Market Open.
355 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 23, 2026, 12:00 am

This summary was created by AI, based on 17 opinions in the last 12 months.

Abbott Labs (ABT) has faced a challenging year marked by a significant share price decline of approximately 30%. Analysts note that the company's ability to deliver on its earnings growth target is critical amid increasing competition and recent struggles. Despite these setbacks, several experts maintain a long-term bullish outlook on the company's growth potential, particularly after recent acquisitions that could enhance its position in the oncology space. While the stock is currently priced below its historical valuation, analysts remain cautious due to recent technical breakdowns in its stock chart and ongoing challenges. The company is expected to report quarterly results soon, prompting a wait-and-see approach from some investors, although there is optimism about future growth driven by a stable market for medical devices and diagnostics.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
Bristol-Myers Squibb, BMY
BUY

Abbott Labs(ABT)

Oct 15, 2020

ABT vs. JNJ Similar businesses. You absolutely need exposure to healthcare. He holds JNJ for the dividend aristocrat qualities. ABT has been impressive. Testing platform has been phenomenal and will continue to ramp up. It's a great addition to portfolios at these levels. Tough choice between the two, but ABT probably has more immediate upside.

Photo of James TelfserJames Telfser
No
Unlock Rating
$107.47

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Abbott Labs(ABT)

Oct 08, 2020
Stockchase Research Editor: Michael O'Reilly This medical device company has has been front and centre during the pandemic -- providing six COVID-19 test kits -- including one now that provides results in 15 minutes. The company's other products help patients with chronic cardiovascular, pulminary, and diabetic issues. The company is launching a new non-finger poking glucose monitoring device -- a game changer. A recent pullback in the share price gives an opportunity to enter with reasonable upside. We would trade this with a $97 stop-loss looking to achieve $128 -- 17% upside. Yield 1.34% (Analysts’ price target is $115.12)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$108.62

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Oct 01, 2020
Their rapid covid test is positive. The company also has a lot of other great products, including interesting products for diabetes. The underlying fundamentals are strong. The equipment side of healthcare is more positive than the drug side.
Photo of Zachary Curry Zachary Curry Unlock Rating
$109.13

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Sep 30, 2020
Their new 15-minute Covid test rallied today. The test works with an app that indicates the user passing the test, hence allowing the user to board planes among other things. This could be a game-changer. This is still a buy despite today's rally.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$108.83

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Abbott Labs(ABT)

Sep 15, 2020
(A Top Pick Sep 12/19, Up 28%) Still buying it around $102. It's a diversified healthcare company including nutritionals and generic drugs, the latter being sold to emerging markets. EM account for 40% of revenues. Medical devices was seeing fine product momentum even before Covid. After Covid, they've been producing testing kits which drives growth. They just announced a 5-minute test, boasting easy-to-use packaging, which will push growth. She expects excellent growth in the next few years, and it pays a solid dividend.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$106.75

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Jul 27, 2020
Biotech has been strong, so steer away from this and go to pharma. Abbot is on the verge of breaking out after basing. There's potential with their vaccine. Pays around 1.5% dividend. He doesn't expect politicians to pressure pharma stocks during this pandemic.
Photo of David BurrowsDavid BurrowsUnlock Rating
$99.98

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Abbott Labs(ABT)

Jul 22, 2020
The pharma sector has been a safe haven during the pandemic. With companies involved with COVID research, he is looking at this closely. He does not own it yet. They have great dividends, but growth has been slow and that problem will not go away anytime soon. Having exposure to pharma would be a good thing.
Photo of Lorne SteinbergLorne Steinberg
No
Unlock Rating
$100.19

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Jun 24, 2020
She is putting new client money into this last week. A diversified health care company with four divisions. They have a pharma group that sells into emerging markets. They also have a medical device, diagnostics and a nutritional division. They have developed both screening and antibody tests for COVID-19. Even if a vaccine is found, testing will be required for quite a while. They have increased their dividend for over 40 consecutive years. Yield 1.62% (Analysts’ price target is $100.75)
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$87.24

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Abbott Labs(ABT)

Jun 18, 2020

ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.

Photo of Darren SissonsDarren SissonsUnlock Rating
$90.28

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Abbott Labs(ABT)

May 13, 2020
(A Top Pick May 14/19, Up 25%) They have held this for years. Their diagnostic division has developed four different COVID testing products, including tests for antibodies. Their recent earnings reflect delays in device growth, which she was not surprised with. However, the diagnostics division is ramping up and benefiting with all the upcoming test requirements. She has been adding to portfolios around $90.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$92.34

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

May 12, 2020
It was a pharma, but spun that operation off. What's left is a company in medical diagnostics. ABT bought two medical companies to build on that. A very good company with a long string of growing dividend payments, like 35 years. His only knock is that its PE has run, so watch that.
Photo of Gordon ReidGordon ReidUnlock Rating
$95.19

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Abbott Labs(ABT)

Jan 14, 2020
(A Top Pick Jan 10/19, Up 25%) A diversified healthcare company that's done well. They sell generic drugs to higher-growth EM (40% of revenues); adult and child nutritional products; and medical products which is showing profit momentum driven by product launches. Aging demographics favour ABT. They don't suffer US drug pricing issues, either. They've increased their dividend for the last 47 years.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$85.89

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Sep 12, 2019
Diversified healthcare company, a space she likes. Not impacted by focus on drug pricing. Sell generics to emerging markets. Also a nutritional business and medical devices, which are growing. Has increased dividend 46-47 years in a row. Yield is 1.50%. (Analysts’ price target is $92.87)
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$85.21

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Abbott Labs(ABT)

Aug 22, 2019
They spun off Abvee that produces Humeria that represents 60% of ABT-T. It was the most successful drug in the world. The area they made acquisitions in have been successful. It is a well managed company. It is not inexpensive. 25 times earnings. When something rises like this then if the earnings don't keep up, the multiples goes up. It is a high valuation stock so be cautious.
Photo of Gordon ReidGordon ReidUnlock Rating
$84.52

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Abbott Labs(ABT)

Aug 13, 2019

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

Photo of Christine PooleChristine Poole
No
Unlock Rating
$86.89

Stock price when the opinion was issued

$90.51

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
Showing 91 to 105 of 221 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TRI.TO 6.34$114.84
ZTS 0.63$76.52
MSCI 0.1$580.95
NVDA -8.57$200.08
BAC 0.54$57.91
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

ESLOY 0$96.36
MSFT 7.08$374.42
META -0.85$563
HLPR.TO -0.02$36.38
VDY.TO 0.38$76.2

Popular Articles

Latest Sell Signals

CLS.TO -34.12$499.31
MBGYY 0$12.93
PLTR -3.025$116.475
ATZ.TO -6.21$156.35
AC.TO 0.25$24.2

Most Recent Experts

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica